

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428

Status	RECRUITING
Phase	Phase 1
Sponsor	AstraZeneca
Enrollment	136 participants

Key Eligibility Criteria

Inclusion (22)

- All Parts:
- Participants with plasminogen level (concentration) within normal range at the Screening Visit.
- All females must have a negative pregnancy test at the Screening Visit and on admission to the study site.
- Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception.
- Females of non-childbearing potential must be confirmed at the Screening Visit.

... and 17 more (see full listing online)

Exclusion (19)

- All Parts:
- History of any clinically important disease or disorder.
- History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
- Participants with known bleeding or coagulation disorders.

... and 14 more (see full listing online)

Locations (5 total)

Research Site, Glendale, California, United States

Research Site, Inverness, Florida, United States

Research Site, Jacksonville, Florida, United States

... and 2 more locations